加载中
NASDAQHealthcareBiotechnology
最新数据
US$38.23
−US$2.05 · -5.09%
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
收盘时
US$38.23
−US$2.05 · -5.09%
盘后
US$38.40
+US$0.17 · +0.44%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
日内区间
当前US$38.23
52周区间
当前US$38.23
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 8.68亿 USD | 7.15亿 USD | 5.82亿 USD | 4.38亿 USD | 3.05亿 USD |
| 销货成本 | 1.98亿 USD | 1.57亿 USD | 1.21亿 USD | 8348.1万 USD | 5551.8万 USD |
| 毛利 | 6.7亿 USD | 5.58亿 USD | 4.61亿 USD | 3.54亿 USD | 2.5亿 USD |
| 研究与开发 | 1.9亿 USD | 1.46亿 USD | 7606.3万 USD | 7088.6万 USD | 3036.7万 USD |
| 销售、一般及管理费用 | 2.72亿 USD | 2.21亿 USD | 1.93亿 USD | 1.63亿 USD | 1.32亿 USD |
| 营业费用 | 4.62亿 USD | 3.67亿 USD | 2.69亿 USD | 2.34亿 USD | 1.62亿 USD |
| 利息收入 | 2192.4万 USD | 1854.2万 USD | 1473万 USD | 312.6万 USD | 22.4万 USD |
| 利息支出 | 1464.9万 USD | 1749.6万 USD | 2375.7万 USD | 1879.5万 USD | 2419.4万 USD |
| 折旧和摊销 | 2533.5万 USD | 2411.2万 USD | 2435.9万 USD | 2338.5万 USD | 1884万 USD |
| 营业利润 | 2.08亿 USD | 1.91亿 USD | 1.92亿 USD | 1.2亿 USD | 8752.8万 USD |
| 净利润 | 1.59亿 USD | 1.45亿 USD | 1.29亿 USD | 1.81亿 USD | 3459.7万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$49.00
上涨空间 28.17%报告持有此股票敞口的交易所交易基金。
Avantis U.S. Small Cap Value ETFAVUV1.07亿0.35%308.51亿 USD0.25%US$119.94+0.25%
Vanguard Morningstar Total Stock Market ETFVTI6129.9万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM4747.56万0.06%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Small-Cap ETFVB4452.98万0.02%1853亿 USD0.03%US$288.16-0.46%
Fidelity Enhanced Small Cap ETFFESM3189.61万0.48%64.1亿 USD0.28%US$45.24-0.48%
Dimensional - US Targeted Value ETFDFAT2738.95万0.09%301.22亿 USD0.33%US$67.42+0.22%
Vanguard Morningstar Small-Cap Growth ETFVBK2552.97万0.06%447亿 USD0.05%US$340.88-1.12%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV2119.33万0.08%268.09亿 USD0.33%US$37.98+0.08%Avantis U.S. Small Cap Value ETFAVUVVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBFidelity Enhanced Small Cap ETFFESMDimensional - US Targeted Value ETFDFATVanguard Morningstar Small-Cap Growth ETFVBKU.S. Small Cap Value Portfolio ETF Class SharesDFSVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
